Clinical Trials Browser

NIH × Head and Neck Neoplasms × pembrolizumab × Clear all

NCT05879484 2025-07-10

Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS

Phase 1/2 Withdrawn

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Lung Neoplasms